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 Synopsis- Biodegradable electrospun membranes of poly-lacticco- glycolic acid 
50:50 were applied to rabbit corneas for 29 days . Membranes were completely 
cleared from the eye by 29 days without eliciting any local or systemic toxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Aim: The aim of this study was to assess the local and systemic response to poly-
lactic co- glycolic acid 50:50 (PLGA) membranes, developed as synthetic 
biodegradable alternatives to the use of human donor amniotic membrane in the 
treatment of limbal stem cell deficiency. 
Methods: PLGA membranes of 2cm diameter and 50Pm thickness were placed on 
one eye of rabbits and secured in place using fibrin glue and a bandage contact lens, 
suturing the eye close with a single stitch. Control animals were treated identically, 
with the absence of the membranes. Plain and microfabricated electrospun 
membranes (containing micropockets which roughly emulate the native limbal niche) 
were examined over 29 days. All animals were subjected to a detailed gross and 
histopathological observation as well as a detailed examination of the eye. 
Results: Application of the membranes both with and without microfabricated 
pockets did not adversely affect animal welfare. There was complete degradation of 
the membranes by day 29. The membranes did not induce any significant local or 
systemic toxicity. Conjunctival congestion and corneal vascularization were noted in 
a few control and PLGA treated animals. Intraocular pressure was normal and the 
retinal status was unaltered. The ocular surface was clear and intact in all animals by 
the end of 29 days.  
Conclusion: Membranes of 50:50 PLGA can be safely applied to rabbit corneas 
without inducing any local or systemic toxicity and these break down completely 
within 29 days. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Limbal stem cell deficiency (LSCD) can be caused by injuries, surgery, disease and 
developmental anomalies causing loss of corneal epithelial stem cells located in the 
limbus and leading to conjunctivalization of the ocular surface. 
Treatments for LSCD range from grafting limbal tissues to transplanting cultured 
limbal epithelial cells (CLET) to more recently transplanting small pieces of limbal 
explants directly onto the ocular surface (simple limbal epithelial transplantation  
(SLET)[1-3].  SLET unlike CLET obviates the need for clean room facilities and cell 
culture technicians, therefore becoming much more accessible[4]. Both CLET and 
SLET procedures are successful in around 70% of patients with LSCD due to 
chemical burns[5-7].  
Human amniotic membrane (hAM) is commonly used in CLET and SLET as a 
sacrificial substrate. It provides support to the transplanted cells ensuring good 
attachment and cell survival on the ocular wound bed. SLET has radically simplified 
the treatment of LSCD, but further improvements could widen availability. A 
synthetic membrane would be more accessible and safer than using hAM.  
Alternate carrier materials have been studied for the transplantation of limbal stem 
cells including coated contact lenses, compressed collagen and recently PLGA 
membranes (poly-lactic co- glycolic acid )[8,9]. PLGA has been extensively used in 
the clinic as dissolvable sutures[10]. Our previous work shows that electrospun PLGA 
membranes based on a 50:50 ratio of glycolic acid to lactic acid broke down within 4 
to 6 weeks in vitro, supported limbal cell expansion as well as hAM in terms of stem 
cell expansion and maintenance without the need for feeder cells[11,12].We also 
showed transfer of cells from these membranes to cornea organ culture models in 
vitro.  
Limbal stem cells are believed to be located within crypts in the limbus and in contact 
with supporting cells which help them retain their stemness[13-15].To mimic  the 
native tissue, we designed a membrane incorporating microfabricated pockets to 
provide protection to the limbal explants that are transplanted onto the ocular 
surface[16].  
In this study we applied PLGA membranes both with and without microfabricated 
pockets to the corneas of rabbits for 29 days. Experiments were done in collaboration 
with an accredited contract research organisation, Vimta Labs Ltd, following 
6FKHGXOH µ<¶ 'UXJV DQG &RVPHWLF ,,$PHQGPHQW 5XOHV IRU DVVHVVLQJ WRSLFDO DQG
systemic toxicity. 
Both membranes broke down completely within 29 days without adverse effects. 
 
Materials 
PLGA membranes were produced by The Electrospinning Company Ltd, UK. PLGA 
50:50 (Corbion, the Netherlands) of molecular weight 44 kg/mol was used in this 
study. Membranes were gamma irradiated (Steris AST, Swindon, UK), packaged and 
sent to India by World Courier (London, UK). 
New Zealand rabbits were sourced from Delve Labs, Hyderabad. 
Bandage contact lens and Ethicon non-absorbable surgical were from Johnson and 
Johnson Vision care, USA and Tisseel kit (fibrin glue) from Baxter, Austria.  
 
Methods 
The study was performed in compliance with OECD Principles of Good Laboratory 
Practice for the testing of chemicals as specified by International [C(97)186/Final] 
Legislation. The study protocol was approved by the Institutional Animal Ethics 
Committee of VIMTA Labs Limited and abided by the recommendations of the 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
guidelines. 
Experimental Design 
Rabbits (aged 10-13 weeks) were acclimatized for 5 days prior to surgery then 
randomized based on their weight. Fundus examination, intra ocular pressure (IOP) 
measurement and fluorescein dye examination were performed prior to randomization 
to ensure the selected rabbits had normal ocular health. Rabbits were distributed into 
2 groups for both plain and microfabricated membranes; control or sham treated 
group (G1) of 6 rabbits (3 males + 3 females) and PLGA treated (G2) group of 14 
rabbits (7 males + 7 females). Fibrin glue and a bandage contact lens were applied to 
the left eye of G1 rabbits. In G2 rabbits, PLGA membrane was placed on the left eye 
using fibrin glue, followed by the application of bandage contact lens. Before 
performing complete tarsorrhaphy, one drop of 2.5% povidone-iodine was instilled in 
the eye receiving the PLGA membrane or sham treatment. For all animals 
tarsorrhaphy was removed a day prior to sacrifice on days 7, 14 and 28, respectively. 
Surgical procedures were performed under general anesthesia using a combination of 
Ketamine (30mg/Kg body weight) and Xylazine (5mg/Kg body weight). 
Ciprofloxacin eye drops were administered 4 times a day for one week and 
carboxymethyl cellulose drops applied daily. Four rabbits (2 male + 2 female) each, 
from G2 were sacrificed on day 8 and day 15 to study the degradation of the 
membranes in vivo. All remaining animals were sacrificed on day 29. 
A schematic of the experimental protocol is given in figure 2. 
Test Material 
PLGA membranes, 50 µm thick with a mean fiber diameter of 2.74 ± 0.89 µm were 
electrospun[12]. Polymers were dissolved in 1,1,1,3,3,3-hexafluoroisopropanol 
(Sigma Aldrich, Dorset, UK) at a concentration of 20 wt%. Polymer solutions were 
delivered at a constant feed rate of 800 µl/h, using a programmable Harvard 
PHD4400 syringe pump (Harvard Apparatus, Kent, UK) to a blunt tipped stainless-
steel needle with an internal diameter of 0.8 mm. The tip of the needle was in turn 
connected to a positive high voltage unit (Glassman High Voltage Inc. High Bridge, 
NJ, USA) and solutions were electrospun with an applied voltage of 12.5 kV. 
Electrospinning was performed in an environmentally controlled, A1-Safetech, air 
recirculation cabinet at 25°C and a relative humidity of 25%.  For the plain PLGA 
membranes, fibers were deposited onto a grounded, custom built rotating mandrel at a 
distance of 300 mm from the tip of the needle, coated in aluminum foil. For the 
membranes with microfabricated pockets, fibres were deposited onto templates 
prepared via stereolithography[16].  
Following production and quality control assessment by SEM (Phenom G2 Pro, The 
Netherlands), membranes were dried under vacuum at room temperature for 48hrs to 
remove residual solvent, before being die cut into 22 mm diameter discs. The 
membranes were then vacuum sealed in bags prior to terminal sterilization via Ȗ-
irradiation (25-40 kGy) at Steris AST Plc. (Moray Road,Swindon, UK). A schematic 
representation of the production process is given in figure 1. 
Observations 
1. Clinical signs 
Clinical examinations were performed prior to treatment and weekly thereafter. These 
included changes to skin, fur, eyes, mucous membrane, secretions, excretions, 
autonomic activity, gait, posture and response to handling and presence of clonic or 
tonic movements.  
1.1. Body Weight 
Body weights were recorded on days 1, 8, 15, 22 and 29. Fasting body weights for 
interim sacrificed animals were taken one day prior to necropsy.  
2. Ophthalmic investigations 
2.1 Gross ocular observations were performed by visual assessment for signs of 
infection or inflammation. Treated eyes were examined for degradation of scaffold on 
the day of sacrifice after removal of bandage contact lens. 
2.2 Fundus examination and IOP of all rabbits was carried out using a Kowa Digital 
Ophthalmoscope (Welch Allyn, USA) and a Reichert Tono-Pen XL Tonometer 
(Reichart, USA) prior to randomisation and sacrifice.  
2.3Fluorescein was applied to the ocular surface to assess health prior to 
randomisation and on sacrifice days after removal of contact lens and PLGA 
membrane where applicable.  
3. Blood investigations 
Clinical laboratory investigations were performed on days 8, 15 or 29.  Blood was 
collected from the overnight fasted rabbits from the marginal ear vein. 
Haematological parameters were determined using ADVIA, 2120 (Siemens, 
Germany).  
Clinical chemistry parameters were analysed with the help of an automatic 
biochemical analyser (Vitros 250, Johnson & Johnson) using standard kits. 
4. Tissue investigations 
 The animals were fasted overnight, weighed and euthanised under over anesthesia of 
thiopentone sodium.  
4.1 Organ weights 
Adrenals, brain, heart, lungs, kidneys, liver, spleen, testes/uterus and thymus were 
dissected free of fat and weighed wet as soon as possible to avoid drying. 
4.2 Histopathology 
Tissues from sacrificed rabbits were processed in an automatic tissue processor 
(Microm spin tissue processor STP 120-3, Thermo Scientific, USA) and embedded in 
paraffin wax using Microm Embedding center EC350 (Thermo Scientific, USA). 
Tissue sections of 3-ȝ were stained with haematoxylin and eosin in an automatic 
tissue stainer (Microm HMS 740 robotic stainer, Thermo Scientific, USA). A 4-step 
grading system of minimum, mild, moderate and marked was used to rank 
microscopic findings for comparison among groups. 
Statistical Analysis 
The data generated from the rabbits subjected to interim sacrifice on day 8 and 15 was 
not considered for statistical analysis along with the animals sacrificed on day 29 (due 
to variance in the day of sacrifice compared to control animals). The data is expressed 
as mean ± SD. NRUPDOLW\RI WKHGDWDZDVFRQILUPHGXVLQJ'¶$JRVWLQRDQG3HDUVRQ
omnibus test. ANOVA and Kruskal-Wallis tests were used for group comparison of 
non-homogenous data. Parameters showing significance in the Kruskal-Wallis test 
were further analysed with Wilcoxan test to compare each group individually over the 
respective control arm. The data analysis was performed using SAS® 9.2, Enterprise 
Guide version 4.2 (SAS Institute Inc., Cary, NC). All statistical tests were performed 
at 5% level of significance.  
 
Results 
Rabbits from control and PLGA treated groups did not show any treatment related 
abnormal clinical signs during the experimental period. There were no deaths in any 
of the groups of rabbits.  
Body Weight  
No statistical differences were observed in the mean body weights (Supplementary 
table 1) of the different groups of rabbits throughout this study.  
Ophthalmic examination 
The PLGA membranes (plain and microfabricated) appeared intact on the ocular 
surface on day 8. Partial breakdown of the membrane was noted in all animals on day 
15. By day 29, there was complete breakdown of the respective membranes in all 
animals (Fig.3) 
Mild to moderate conjunctival congestion was noted in all animals sacrificed on day 8 
but resolved completely by day 29. In all animals sacrificed on day 8 (both plain and 
microfabricated) PLGA membrane was found adhered to the ocular surface. 
Vascularization (<2 clock hours) was noted in 1/4 and 3/6 animals that received the 
plain PLGA membrane at the end of 15 and 29 days, respectively. Control animals 
showed epithelial defects and stromal thinning in 2/6 (day 15) and 1/6 (day 29) 
animals, respectively. Corneal vascularization (2-4 clock hours) was noted in 3/6 
animals of the pocket PLGA treated animals and in 3/6 of control animals at the end 
of the 29 days.  
There was no significant change to the IOP when compared to the control animals 
(Supplementary figure 1). This was true for both membranes with and without 
microfabricated pockets. Similarly, no abnormalities were detected in the retina of 
any of the animals before or after treatment with the PLGA membranes. A summary 
of the ophthalmic observations is given as a table in figure 3. 
 
Hematology 
In animals that received the plain membrane, a significant decrease in MCHC (p
0.01), RBC distribution width (p UHODWLYHDQGDEVROXWHPRQRF\WH FRXQWV p
0.05) and absolute lymphocyte counts (p  was observed compared to control 
group. A significant increase in relative basophil count (pZDValso observed in 
rabbits treated with the test membrane compared to the control group (Table 3). 
In animals that received the pocket membranes, a significant increase in absolute 
lymphocyte counts (p  ZDV REVHUYHG LQ UDEELWV WUeated with the test items 
compared to the control animals. No other parameter varied significantly between the 
two groups (Table 1). 
 
Clinical Chemistry 
ALKP (p  DQG **7 p  ZHUH VLJQLILFDQWO\ LQFUHDVHG LQ UDEELWV WUHDWHG
with plain membranes compared to control rabbits and there was a significant 
decrease in creatinine (pDQGWRWDOELOLUXELQpYDOXHVwhen compared to 
control rabbits (Table 2). 
In animals that received pocket membranes, there was a significant decrease in ALT 
values (pand a significant increase in BUN (pYDOXHs when compared 
to control rabbits. All other parameters were comparable in both groups (Table 2) 
 
Organ Weights 
There were no significant changes in the absolute or relative organ weights in male 
and female rabbits that received the plain membrane compared to the control animals.  
In the animals with the pocket membranes, absolute (pDQGUHODWLYHp
weights of the liver were significantly higher in the treated group compared to the 
control group (Supplementary table 2).  
 
Gross Pathology 
There were no gross pathological findings indicative of inflammation or immune 
response in any of the rabbits treated with plain or pocket membranes or with sham 
treatment. 
 
Histopathology 
Hyperplasia of corneal epithelium and remodeling of anterior stromal collagen fibers 
were noted in 1/6 control animals (sacrificed on day 29) of the plain membrane group 
(Supplementary table 3). The same was noted in 2/6control animals and 4/6 animals 
that received the pocket membrane (day 29; supplementary table 4). Three rabbits that 
had the pocket membrane showed infiltration of heterophils at the filtration angle 
(Supplementary table 4).  
There were no lesions observed in the retina in any of the animals examined 
irrespective of whether animals received PLGA membranes or not.  
In the liver, focal chronic inflammation was noted in 1/6 (plain PLGA) and 
mineralization of hepatocytes in 1/6 (pocket PLGA) animals. Basophilic tubules and 
mineralization was noted in the kidneys of 1/6 animals that received the plain and 
pocket PLGA membranes, respectively.  Increased alveolar macrophages were noted 
in 1/6 animals that received both plain and pocket PLGA membranes. All other 
histological changes were comparable between the control and PLGA treated animals.  
 
Discussion 
PLGA is biodegradable, biocompatible, FDA approved and has been used in several 
applications including drug delivery. The success of PLGA as a product lies in the 
IDFW WKDW LW¶V degradation is largely driven by hydrolytic mechanisms rather than 
enzymatic breakdown and that it breaks down to lactic acid glycolic acid both readily 
handled by the body.  The rate of breakdown of PLGA will depend on the ratio of 
polylactic acid to polyglycolic acid, its location in the body and its bulk composition. 
Thus there is minimal systemic toxicity reported with the use of PLGA in the 
clinic[10,17,18]. In addition, the ability to alter its degradation properties by simply 
altering the ratio of the individual monomers has made this the material of choice for 
a range of applications.  
PLGA based materials have also been tested for a number of applications in the eye 
especially in developing ocular drug delivery systems such as implants and micro-or 
nano-particles. The efficacy of PLGA in delivering anti-inflammatory agents to 
reduce inflammation following cataract surgery has been reported[19]. A study in 
rabbits showed that the PLGA films implanted in the sub-conjunctival space were 
well tolerated during the study period (6months) with no significant inflammatory 
reaction indicative of a rejection[20]. Further PLGA scaffolds were shown to support 
the porcine and rabbit derived corneal endothelium and retinal pigment epithelial 
cells[21] suggesting that the material might be suitable for use in cell therapy since it 
offered sufficient support for the cells to grow and mature exhibiting normal cellular 
characteristics with minimal cell toxicity.  
It is important in designing material for the clinic to use a recognised sterilisation 
technique. In developing this PLGA membrane for clinical use we used gamma 
radiation at 25 to 40 kGy with an average dose per run of 29.4 kGy. In our previous 
publication which formed part of the data which was submitted to the Indian health 
regulatory authority to obtain approval for a first in man study we studied the impact 
of gamma radiation on membrane stability and on the ability of the membranes to 
support outgrowth of limbal cells from limbal tissue explants[12]. 
Gamma radiation accelerated the degradation of the PLGA membranes however, their 
ability to support limbal epithelial cell expansion, especially of the stem cell 
population, was unaffected. We show in the study that 50% of the cells cultured on 
gamma irradiated membranes were proliferating (as determined by positive BrdU 
staining) and there was good outgrowth from explants placed on the irradiated 
membranes as assessed using DAPI staining and Rose Bengal staining[12]. Thus 
gamma radiation while accelerating the breakdown of the membranes (which was 
actually beneficial for this application) had no adverse effects on limbal explanted 
growth. 
We also showed that these membranes in addition to being sterilised could be 
packaged and stored at -20C for more than 2 years and shipped long distance without 
altering their  material properties[12].  
The motivation behind the current study is that prior to any first in man safety study it 
is necessary to demonstrate that these membranes do not induce local or systemic 
toxicity when applied to the cornea of a relevant animal model. The results we 
obtained showed that membranes degraded within 29 days without causing significant 
topical or systemic toxicity. 
While temporary conjunctival congestion was noted in all animals on day 8, persistent 
vascularization of the corneal surface (2-4 clock hours) was noted in both sham and 
treated animals indicating the response was primarily to the surgical procedure. 
Fluorescein staining showed clear and intact ocular surface in all animals except one 
control animal that had stromal thinning. Hematological parameters showed 
significant but minor changes in lymphocyte and monocyte counts in the test animals-
both decreases and increases but all within the normal expected range of clinical 
values for these animals. As the gross and individual organ histology findings did not 
indicate sustained inflammation or infection, these changes were considered to be 
adaptive, consistent with the expected immune response to the breakdown of the 
PLGA material. 
Similarly, while there were significant decreases in the creatinine and total bilirubin 
levels in plain PLGA treated animals, significant increases in ALKP and GGT values, 
an increase in BUN values and a decrease in the ALT values in the pocket treated 
animals compared to the control animals these were again within the normal range for 
these animals and there was no histological evidence of any adverse reaction to the 
PLGA membranes.  
There was a significant increase in the liver weight for animals that received the 
pocket membrane but again no evidence of any correlation with clinical 
histopathological findings as would occur with hepatocellular hypertrophy which can 
occur in response to toxicity. We suggest the increase in the liver weight in all the 
animals of pocket PLGA treated animals might be indicative of a mild inflammatory 
response. In an earlier study[11] in which we implanted electrospun sheets of various 
ratios of PLA to PGA into the flanks of rats we found a  vigorous macrophage 
response associated with scaffold breakdown but little evidence of any lymphocytic 
response.  
 
In conclusion, these toxicity studies showed no evidence of topical or systemic 
toxicity in response to the placing of these membranes on the cornea of rabbits.  
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Figure legends 
 
Figure 1: Schematic of the production and sterilisation route for PLGA electrospun 
membranes (plain and microfabricated).  
The membrane design (top panel) involved the fabrication of the membranes in 
collaboration with The Electrospinning Company which ensured both reproducibility 
and scaling-up possibilities. For the production of the microfabricated membranes, 
first polymeric ring templates of 1.6 cm of diameter were created using a layer-by-
layer photocuring approach in which a blue laser (473 nm) was directed into a bath of 
Polyethylene glycol diacrylate (PEGDA) containing camphorquinone (CQ) during 
intervals of 15-60 seconds.The process involved the use of a computer aided design 
comprising two layers (Layer 1 acted as a base and it did not contain microfeatures; 
Layer 2 contained a total of 6 horse-shaped microfeatures of sizes ranging 350-
500µm). The combination of these two layers resulted in the creation ofthe polymeric 
rings which acted as templates. These were mounted onto a 2 mm thick grounded 
electroplated aluminium sheet and then membranes were electrospun over them. This 
resulted inmicrofabricated PLGA electrospun rings (pocket membranes).The 
manufactured membranes were characterised and tested in vitro using both rabbit and 
human corneal cells. After product design optimisation and in vitro testing, prototype 
membranes were produced and sterilised using gamma-irradiation. PLGA membranes 
were then vacuum-packed with a range of desiccants to ensure moisture stability. The 
optimised and sterilised membranes (plain and microfabricated) were then used for 
the evaluation of local and systemic toxicity in rabbits. 
 
Figure 2: Schematic of the experimental protocol in rabbits 
This protocol was used for both the study of the plain PLGA membrane and of the 
 PLGA membrane containing microfabricated pockets which were conducted as two 
separate experiments with individual control groups. 
 
Figure 3: Breakdown of plain and pocket PLGA membranes on corneas of rabbits 
Representative images of the residual plain PLGA membrane on the ocular surface of 
the rabbit on days 8,15 and 29 is shown in figure 3A. Representative image of the 
sham treated eye on day 29 is shown for comparison. In panel B are shown 
representative images of the ocular surface of control eyes and eyes treated with 
PLGA membranes after fluorescein staining on days 8, 15, and 29. The staining seen 
in these images are of the PLGA membranes that remained attached to the ocular 
surface. Panel C is a summary table of the ocular findings in the animals treated with 
plain or pocket PLGA and their respective control animals. 
 
Supplementary figure 1: Examination of the effect of plain and pocket PLGA 
membranes on the fundus of the eye and on intra-ocular pressure. 
A shows photographs of the retina of the rabbit eyes before and after application of 
plain membranes and membranes containing microfabricated pockets. 
B shows the intraocular pressures recorded on days 7, 15 and 29 for rabbits which did 
not receive membranes and for rabbits which received plain membranes or 
membranes with microfabricated pockets. 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1: Hematological values 
Parameter Sham Treated Plain 
membrane 
Sham Treated Pocket 
membrane 
WBC 
(103Cells/µL) 
7.73 + 1.10 6.46+ 2.09 6.62 + 2.01 8.63 + 1.30 
RBC 
(106Cells/µL) 
5.43 + 0.61 5.66+ 0.25 5.43 + 0.47 5.44 + 0.67 
Hb (g/dL) 11.6 + 1.1 11.9 + 0.7 11.3 + 0.7 11.2 + 0.7 
Hct (%) 36.3 + 3.4 39.1 + 1.8 37.9 + 2.2 38.1 + 2.7 
MCV (fL) 67.1 + 4.0 69.1 + 2.1 69.9 + 3.9 70.4 + 5.2 
MCH (pg) 21.5 + 1.5 21.1 + 0.9 20.8 + 0.8 20.8 + 1.2 
MCHC (g/dL) 32.0 + 0.6 30.5+0.5 
(**-) 
29.8 + 0.5 29.6 + 0.7 
RDW (%) 15.8 + 0.9 14.3 + 1.3 
(*-) 
15.4 + 0.8 14.5 + 1.2 
Platelets 
(103Cells/µL) 
634 + 197 605 + 93 589 + 184 505 + 122 
Relative DLC (103 cells/µl) 
Neut (%) 17.9 + 9.4 18.6+ 11.0 16.1 + 7.3 17.8 + 8.1 
Lymp (%) 74.4 + 9.9 73.5+ 10.5 75.8 + 8.2 74.0 + 8.3 
Mono (%) 3.2 + 0.5 2.5 + 0.6 
(*-) 
2.3 + 1.1 3.2 + 1.7  
Eosi (%) 1.0 + 0.5 0.9 + 0.7 1.1 + 0.4 1.1 + 0.3 
Baso (%) 3.1 + 1.0 4.4 + 0.9 
(*+) 
4.3 + 1.8 3.4 + 1.5 
Luc (%) 0.4 + 0.5 0.2 + 0.1 0.5 + 0.3 0.4 + 0.2 
Absolute DLC (x103 cells/µl) 
Neut 
(103 cells/µl) 
1.46 + 1.06 1.37+ 1.26 1.15 + 0.82 1.61 + 0.88 
Lymp 
(103 cells/µl) 
5.55 + 0.35 4.58+ 0.88 
(*-) 
4.93 + 1.16 6.32 + 0.48 
Mono 
(103 cells/µl) 
0.25 + 0.06 0.16+ 0.05 
(*-) 
0.15 + 0.07 0.29 + 0.15 
Eosi 
(103 cells/µl) 
0.08 + 0.05 0.06+ 0.05 0.08 + 0.05 0.10 + 0.04 
Baso 
(103 cells/µl) 
0.24 + 0.07 0.28+ 0.09 0.27 + 0.12 0.28 + 0.11 
Luc 
(103 cells/µl) 
0.04 + 0.05 0.01+ 0.00 0.03 + 0.02  0.04 + 0.02 
N=6 (each of sham treated and PLGA treated animals), *+ Significant increase when 
compared to control (p<0.05); *- Significant decrease when compared to control 
(p<0.05); **+ Significant increase when compared to control (p<0.01); **- 
Significant decrease when compared to control (p<0.01) 
 
 Table 2: Clinical chemistry values 
 
Parameter Sham 
Treated 
Plain 
membrane 
Sham 
Treated 
Pocket 
membrane 
Glucose 
(mg/dl) 
140 + 10 136 + 19 143 + 19 172 + 27 
BUN 
(mg/dl) 
19.8 + 3.6 16.9 + 3.4 19.8 + 2.2 25.1 + 2.9 
(**+) 
Creatinine 
(mg/dL 
0.91 + 0.16 0.69 + 0.11 
(*-) 
0.78 + 0.10 0.77 + 0.12 
Na+(mmol/L) 142 + 4.0 146 + 3.0 154 + 16 156 + 4.0 
K+ (mmol/L) 4.1 + 0.4 3.6 + 0.2 3.8 + 0.4 4.6 + 0.3 
Ca+ (mg/dL) 14.02+ 0.42 14.64+ 0.69 13.81+ 0.25 15.52+ 0.27 
Phosphate (mg/dL) 5.32 + 0.57 5.60 + 0.76 6.08 + 0.27 5.54 + 0.79 
T.Cholesterol(mg/dl) 55 + 10 47 + 3.0 58 + 21 54 + 18 
Triglyceride 
(mg/dL) 
53 + 6.0 73 + 33 91 + 57 139 + 80 
T.Protein(g/dL) 6.30 + 0.40 6.53 + 0.64 6.41 + 0.33 6.35 + 0.36 
Albumin (g/dL) 4.16 + 0.31 4.39 + 0.53 4.48 + 0.27 4.46 + 0.53 
A/G Ratio 2.04 + 0.57 2.11 + 0.47 2.35 + 0.25 2.41 + 0.54 
AST(U/L) 35 + 10 45 + 32 38 + 16 27 + 5 
ALT(U/L) 62 + 17 72 + 23 60 + 13 42 + 13 (*-) 
ALP(U/L 98 + 26 131 + 16 (*+) 156 + 28 126 + 31 
GGT (U/L) 8.0 + 1.0 11 + 1.0 (**+) 9.0 + 2.0 9.0 + 1.0 
T.Bilirubin(mg/dL) 0.55 + 0.09 0.40 + 0.04 
(**-) 
0.41 + 0.07 0.42 + 0.06 
Glo(g/dL) 2.14 + 0.46 2.14 + 0.41 1.92 + 0.18 1.88 + 0.19 
N=6 (each of sham treated and PLGA treated animals), *-significant decrease 
compared to sham treatment (p<0.05); **- significant decrease compared to sham 
treatment (p<0.01); *+ significant increase compared to sham treatment (p<0.05); **+ 
significant increase compared to sham treatment (p<0.01) 
 
 
 
 
 
  
 
 
 
 
